Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.38 |
| ▸ | XDH | P47989 | 3/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734229 | 0.92 | XDH (0.41) | GCKXDHHDAC1HDAC2HDAC8 | |
| SCHEMBL1075816 | 0.91 | GCK (0.41) | GCK | |
| SCHEMBL1076960 | 0.88 | GCK (0.36) | GCK | |
| SCHEMBL1075448 | 0.87 | GCK (0.36) | GCK | |
| SCHEMBL1076711 | 0.86 | CHEK2 (0.36) | GCKXDH | |
| SCHEMBL564696 | 0.84 | GCK (0.36) | GCKXDH | |
| SCHEMBL1076539 | 0.83 | GCK (0.42) | GCK | |
| SCHEMBL564574 | 0.82 | SYK (0.38) | GCKXDH | |
| SCHEMBL12734076 | 0.82 | CHEK2 (0.37) | XDHHDAC1HDAC2HDAC8 | |
| SCHEMBL1075410 | 0.80 | GCK (0.34) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673942-B2 | Fused ring compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098297-A1 | FUSED RING COMPOUNDS AND USE THEREOF | GCKR, GPR119, SLC5A1 | GCK 4/4885XDH 806/4885MAP3K7 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.